E-viri
Recenzirano
Odprti dostop
-
Ott, Patrick A.; Hu-Lieskovan, Siwen; Chmielowski, Bartosz; Govindan, Ramaswamy; Naing, Aung; Bhardwaj, Nina; Margolin, Kim; Awad, Mark M.; Hellmann, Matthew D.; Lin, Jessica J.; Friedlander, Terence; Bushway, Meghan E.; Balogh, Kristen N.; Sciuto, Tracey E.; Kohler, Victoria; Turnbull, Samantha J.; Besada, Rana; Curran, Riley R.; Trapp, Benjamin; Scherer, Julian; Poran, Asaf; Harjanto, Dewi; Barthelme, Dominik; Ting, Ying Sonia; Dong, Jesse Z.; Ware, Yvonne; Huang, Yuting; Huang, Zhengping; Wanamaker, Amy; Cleary, Lisa D.; Moles, Melissa A.; Manson, Kelledy; Greshock, Joel; Khondker, Zakaria S.; Fritsch, Ed; Rooney, Michael S.; DeMario, Mark; Gaynor, Richard B.; Srinivasan, Lakshmi
Cell, 10/2020, Letnik: 183, Številka: 2Journal Article
Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. This analysis of 82 patients demonstrated that the regimen was safe, with no treatment-related serious adverse events observed. De novo neoantigen-specific CD4+ and CD8+ T cell responses were observed post-vaccination in all of the patients. The vaccine-induced T cells had a cytotoxic phenotype and were capable of trafficking to the tumor and mediating cell killing. In addition, epitope spread to neoantigens not included in the vaccine was detected post-vaccination. These data support the safety and immunogenicity of this regimen in patients with advanced solid tumors (Clinicaltrials.gov: NCT02897765). Display omitted •The personalized neoantigen vaccine Neo-PV-01 plus nivolumab is feasible and safe•NEO-PV-01 plus nivolumab stimulates durable neoantigen-specific T cell reactivity•NEO-PV-01-specific T cells have cytotoxic potential and can traffic to the tumor•NEO-PV-01 induces epitope spreading consistent with vaccine-mediated tumor cytotoxicity In a phase Ib clinical trial, Ott et al. demonstrate feasibility, safety, and immunogenicity of the combination of personalized neoantigen vaccines and PD-1 inhibition in patients with advanced solid tumors. Vaccine-induced T cells persist over time, exhibit cytotoxic potential, and can migrate to tumors. Epitope spread and major pathologic tumor responses were detected following vaccination.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.